UY25804A1 - Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3 - Google Patents

Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3

Info

Publication number
UY25804A1
UY25804A1 UY25804A UY25804A UY25804A1 UY 25804 A1 UY25804 A1 UY 25804A1 UY 25804 A UY25804 A UY 25804A UY 25804 A UY25804 A UY 25804A UY 25804 A1 UY25804 A1 UY 25804A1
Authority
UY
Uruguay
Prior art keywords
alkyl
independently
ccr
antagonists
derivatives
Prior art date
Application number
UY25804A
Other languages
English (en)
Inventor
Robert Stephen Wilhelm
David Bernard Smith
Denis John Kertesz
Leyi Gong
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY25804A1 publication Critical patent/UY25804A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Esta invención se refiere a derivados de 4-aroilpiperidina de fórmula (I), en la que: Ar1 y Ar2 son, independientemente entre sí, arilo o heteroarilo; R y R1 son, independientemente entre sí, H o alquilo; R2 es un grupo alquilo, heteroalquilo, arilo, aralquilo, heteroarilo, heterociclilalquilo; X es un grupo seleccionado de: a) -C(O)N(R3)-; b) -N(R4)C(O)N(R3)-; c) -N(R4)C(S)N(R3)-; -SO2N(R3)-; ó -N(R4)SO2N(R3)-; en donde: R3 y R4 son, independientemente entre sí, H, alquilo, aralquilo, heteroaralquilo, heterocicloalquilo, heteroalquilo; y Y es un enlace o alquileno; y profármacos, isómeros individuales, mezclas de isómeros, y sales farmacéuticamente aceptables de los mismos. Asimismo, la invención se refiere a composiciones farmacéuticas que las contienen, métodos para su utilización y métodos para preparar estos compuestos. Dichos compuestos son antagonistas del receptor CCR-3 y, por tanto, son útiles en el tratamiento del asma. Ej. no limitante: N-[1-[4-(3,4-diclorobenzoil)piperidin-1-ilmetil]-2-metilpropil]-4-metoxibenzamida.
UY25804A 1998-11-17 1999-11-16 Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3 UY25804A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10879698P 1998-11-17 1998-11-17

Publications (1)

Publication Number Publication Date
UY25804A1 true UY25804A1 (es) 2001-07-31

Family

ID=22324087

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25804A UY25804A1 (es) 1998-11-17 1999-11-16 Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3

Country Status (22)

Country Link
US (1) US6140344A (es)
EP (1) EP1131291B1 (es)
JP (1) JP3475177B2 (es)
KR (1) KR20010087395A (es)
CN (1) CN1163484C (es)
AR (1) AR029150A1 (es)
AT (1) ATE280157T1 (es)
AU (1) AU757747B2 (es)
BR (1) BR9915403A (es)
CA (1) CA2350722A1 (es)
CO (1) CO5150176A1 (es)
DE (2) DE69921351T2 (es)
ES (2) ES2230899T3 (es)
FR (1) FR2785902B1 (es)
GB (1) GB2343891B (es)
IT (1) IT1307062B1 (es)
PE (1) PE20001303A1 (es)
PT (1) PT1131291E (es)
TR (1) TR200101155T2 (es)
UY (1) UY25804A1 (es)
WO (1) WO2000029377A1 (es)
ZA (1) ZA200103249B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486180B1 (en) 1998-12-18 2002-11-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2482100A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2350730A1 (en) * 1998-12-18 2000-06-22 George V. Delucca N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
PL350904A1 (en) 1999-03-26 2003-02-10 Astrazeneca Ab Novel compounds
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
TWI227231B (en) * 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
CZ20031195A3 (cs) 2000-09-29 2003-09-17 Glaxo Group Limited Morfolinacetamidové deriváty
FR2821356A1 (fr) * 2001-02-23 2002-08-30 Cerep Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations
GB0114699D0 (en) 2001-06-15 2001-08-08 Novartis Ag Organic compounds
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
SE0102809D0 (sv) * 2001-08-22 2001-08-22 Astrazeneca Ab Novel compounds
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
RU2005129550A (ru) 2003-02-27 2006-07-27 Ф.Хоффманн-Ля Рош Аг (Ch) Антагонисты рецептора ccr-3
MXPA05009771A (es) 2003-03-14 2005-10-26 Ono Pharmaceutical Co Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo.
WO2004092169A1 (ja) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
MXPA06004304A (es) * 2003-10-24 2006-06-05 Hoffmann La Roche Antagonistas del receptor ccr-3.
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
WO2006129679A1 (ja) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
BRPI0708731A2 (pt) 2006-03-10 2011-06-07 Ono Pharmaceutical Co derivado heterocìclico nitrogenado, e agente farmacêutico compreendendo o derivado como ingrediente ativo
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
EP2787346B1 (en) 2011-11-28 2017-06-21 National University Corporation Nagoya University Biomarker for lymphocytic infundibuloneurohypophysitis, and use applications thereof
EP3681286B1 (en) * 2017-09-13 2021-12-15 Syngenta Participations AG Microbiocidal quinoline (thio)carboxamide derivatives
BR112020004933A2 (pt) 2017-09-13 2020-09-15 Syngenta Participations Ag derivados microbiocidas de (tio)carboxamida de quinolina
US11266146B2 (en) 2017-09-13 2022-03-08 Syngenta Participations Ag Microbiocidal quinoline (thio)carboxamide derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK159420C (da) * 1983-03-09 1991-03-11 Ciba Geigy Ag N-(piperidinyl-alkyl)-carboxamider og salte deraf, farmaceutiske praeparater indeholdende disse forbindelser samt anvendelsen af forbindelserne til fremstilling af antipsykotiske farmaceutiske praeparater
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
JPH041128A (ja) * 1990-03-07 1992-01-06 Ajinomoto Co Inc 抗不整脈薬
US5143923B1 (en) * 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
DK60893D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Piperidinderivater, deres fremstilling og anvendelse
WO1995000481A1 (en) * 1993-06-23 1995-01-05 Merrell Dow Pharmaceuticals Inc. Piperidin-1-yl-2,2-dialkylpropanonearylsulfonamide derivatives
US5728835A (en) * 1993-12-27 1998-03-17 Toa Eiyo, Ltd. Substituted cyclic amine compound, production process thereof and pharmaceutical composition for circulatory organ use containing the same
EP0661266A1 (en) * 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituted cyclic amine compounds as 5HT2 antagonists
JPH09249566A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ピペリジン化合物含有ケモカイン受容体拮抗剤
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US6133319A (en) * 1996-06-27 2000-10-17 Smithkline Beecham Corporation IL-8 receptor antagonists
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
JP2002510327A (ja) * 1997-07-25 2002-04-02 メルク エンド カンパニー インコーポレーテッド 環状アミンケモカイン受容体活性調節剤
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AU2335699A (en) * 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
DE69921351T2 (de) 2006-03-09
PE20001303A1 (es) 2000-11-30
ZA200103249B (en) 2002-07-22
GB2343891A (en) 2000-05-24
ITTO990990A1 (it) 2001-05-16
GB2343891B (en) 2001-05-30
EP1131291B1 (en) 2004-10-20
FR2785902B1 (fr) 2003-09-26
KR20010087395A (ko) 2001-09-15
DE19955340A1 (de) 2000-05-31
ES2230899T3 (es) 2005-05-01
AU1045900A (en) 2000-06-05
CN1326441A (zh) 2001-12-12
JP2002529531A (ja) 2002-09-10
WO2000029377A1 (en) 2000-05-25
ATE280157T1 (de) 2004-11-15
BR9915403A (pt) 2001-08-14
PT1131291E (pt) 2005-01-31
DE69921351D1 (de) 2004-11-25
CO5150176A1 (es) 2002-04-29
EP1131291A1 (en) 2001-09-12
ES2160525B1 (es) 2002-06-16
ES2160525A1 (es) 2001-11-01
US6140344A (en) 2000-10-31
IT1307062B1 (it) 2001-10-23
FR2785902A1 (fr) 2000-05-19
GB9926969D0 (en) 2000-01-12
AR029150A1 (es) 2003-06-18
CA2350722A1 (en) 2000-05-25
TR200101155T2 (tr) 2001-09-21
JP3475177B2 (ja) 2003-12-08
ITTO990990A0 (it) 1999-11-16
AU757747B2 (en) 2003-03-06
CN1163484C (zh) 2004-08-25

Similar Documents

Publication Publication Date Title
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
ES2154167B1 (es) Aminoderivados ciclicos antagonistas del receptor ccr-3.
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
UY27322A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
ATE250590T1 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
AR032877A1 (es) Inhibidores alquil c(1-6)-4-amino-azepan-3-onicos de proteasas, composiciones farmaceuticas que los comprenden, intermediarios utiles en la preparacion de tales compuestos, procedimiento para la sintesis de dichos inhibidores, y uso de dichos inhibidores en la fabricacion de medicamentos
CO5180642A1 (es) Compuestos sustituidos de piperidina, procesos para su prepa racion, composiciones farmaceuticas que los contienen y su utilizacion
DE60132309D1 (de) Amin-derivate zur behandlung von apoptosis
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PA8495101A1 (es) Derivados de 13-metileritromicina
MY133445A (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives
UY25079A1 (es) Derivados de azetidinas útiles como antagonistas de las taquicininas y sus intermediarios
AR015446A1 (es) Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
BR0214674A (pt) Derivados 4-piperdinil alquilamina como antagonistas do receptor muscarìnico
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
BR0207795A (pt) Derivados de ácido alcoxicarbonilamino benzóico ou alcoxicarbonilamino tetrazolil fenila como antagonistas de ip
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR035730A1 (es) Derivados de 2-arilamino-2,3-dihidrotiazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento
DE602004016177D1 (de) Methylindole und methylpyrrolopyridine als alpha-1-adrenerge agonisten
UY26972A1 (es) Nuevos antagonistas de neuroquinina, procedimiento para su preparación y composiciones farmacéuticas que contienen estos compuestos
ECSP951512A (es) Antagonistas de neuroquinina

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090417